Comparison of changes in serum prostate specific antigen in prostate cancer patients treated either with flutamide or stilboestrol monotherapy
Prostate cancer is a disease of males. Though commoner in the elderly, cases are beginning to be reported in the younger population. It is the commonest cancer diagnosed in males. Risk factors include ageing, genetic/familial factors, racial predilection, increased fat diet, and hormonal imbalance....
Main Authors: | O F Otobo, P D Ekwere, E O Nkposong, K Omoruyi, T Ugbem, E E Eyam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Nigerian Journal of Medicine |
Subjects: | |
Online Access: | http://www.njmonline.org/article.asp?issn=1115-2613;year=2020;volume=29;issue=1;spage=94;epage=99;aulast=Otobo;type=0 |
Similar Items
-
Flutamide-induced hepatotoxicity: A case report
by: Omer M. Kassid, et al.
Published: (2022-06-01) -
Acute liver failure and liver transplantation secondary to flutamide treatment in a prostate cancer patient
by: Pablo A. Rojas, et al.
Published: (2020-11-01) -
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01) -
Voltammetric study of ds-DNA–flutamide interaction at carbon paste electrode
by: Pradeep K. Brahman, et al.
Published: (2016-11-01) -
Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications
by: José María Mora-Rodríguez, et al.
Published: (2023-10-01)